In conclusion, this is the first report describing that ZBTB16‐RARA+AML are characterized by high incidence of ARID1A mutations, and suggesting the involvement of the SWI/SNF chromatin remodeling complexes in the clinical presentation of this AML subtype. This evidence concerns the gene SMARCA1 and acute myeloid leukemia.